Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
18.01
-0.58 (-3.12%)
At close: Apr 28, 2026, 4:00 PM EDT
17.65
-0.36 (-2.00%)
After-hours: Apr 28, 2026, 7:07 PM EDT
Zenas BioPharma Employees
Zenas BioPharma had 167 employees as of December 31, 2025. The number of employees increased by 37 or 28.46% compared to the previous year.
Employees
167
Change (1Y)
37
Growth (1Y)
28.46%
Revenue / Employee
$59,880
Profits / Employee
-$2,261,898
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 167 | 37 | 28.46% |
| Dec 31, 2024 | 130 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| Pharming Group | 407 |
| UroGen Pharma | 291 |
| KalVista Pharmaceuticals | 275 |
| uniQure | 221 |
| EyePoint | 214 |
| Septerna | 130 |
| DBV Technologies | 117 |
ZBIO News
- 11 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock - GlobeNewsWire
- 6 weeks ago - Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Zenas BioPharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewsWire
- 2 months ago - Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - These 20 stocks are strong choices for momentum investors - Market Watch